Medscheme released updated MEDICINE EXCLUSION LIST APRIL 2023
Some items listed as REQUIRING PRE-AUTHORISATION:
- Forxiga (Dapagliflozin)
- Byetta (Exenatide)
- Janumet (Metformin/Sitagliptin)
- Onglyza (Saxagliptin)
- Januvia (Sitagliptin)
- Galvus (Vildagliptin) + including Metformin combinations
- Liptruzet (Atorvastatin/Ezetimibe)
- Ezetrol (Ezetimibe)
- Inegy(Ezetimibe/Simvastatin)
Details regarding the EXCLUDED ITEMS:
- Trulicity (Dulaglutide)
- Jardiance (Empagliflozin)
- Xultophy (Insulin Degludec and Liraglutide)
- Soliqua (Insulin Glargine and Lixisenatide)
- Victoza (Liraglutide)
- Synjardy (Metformin and Empagliflozin)
- Ozempic (Semaglutide)
Recent Posts
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse
The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
The Market Dynamics of Track One Patent Strategy in Pharmaceuticals
In the interconnected landscape of pharmaceutical regulation and innovation, the Track One patent strategy in pharmaceuticals serves as an important component that influences the timing of mar...
Ending Unproven Fertility Treatments: NICE Calls for Evidence-Based Care in Clinics
Unproven fertility treatments—a term referring to add-on procedures without robust clinical evidence—have come under renewed scrutiny in the UK. Many prospective parents want to know: Why are unproven fertility treatments being discouraged, and what does this mean for fertility clinic choices...